Cronos Group Inc. (CRON) AI Stock Analysis

Cronos Group Inc. is an international cannabinoid firm that manufactures, markets, and distributes hemp-derived supplements and cosmetic items in the United States through brands such as Lord Jones and Happy Dance. The company also cultivates, produces, and markets cannabis for medical and adult-use consumer segments. Its medical wellness portfolio operates under the PEACE NATURALS brand, offering dried cannabis, pre-rolls, edibles, concentrates, and extracts through wholesale channels and direct-to-client sales. In adult-use markets, Cronos Group markets brands including Spinach. Founded in 2012 and based in Toronto, Canada, the company exports dried cannabis and cannabis oils internationally to markets such as Germany, Israel, and Australia.

Cronos Group increased its annual revenue from $64.6M in FY2021 to $149.2M in FY2025, recording a 5-year revenue CAGR of 26.1%. Over that timeframe, gross margin recovered from -27.3% in FY2021 to 41.4% in FY2025, while operating margin improved from -452.2% to -12.0%. Net income stood at -$9.6M in FY2025 with an EPS of $0.03, compared to a net loss of -$396.1M in FY2021. For the trailing twelve months, revenue reached $179.1M with an operating margin of 15.4% and net profit margin of 39.1%. In the quarter ended June 30, 2026, quarterly revenue climbed 58.4% year-over-year, and earnings grew 126.8%.

As of June 30, 2026, Cronos Group held $797.0M in cash and short-term investments alongside total debt of $1.3M, leaving a net cash position of $795.7M. The balance sheet carried a current ratio of 16.18 and a debt-to-equity ratio of 0.00 against $1.07B in shareholders' equity. Operating cash flow rose to $26.3M in FY2025, resulting in free cash flow of $151,611 after capital expenditures of $26.2M. The company also deployed $9.9M toward share buybacks in FY2025.

At a last close of $3.21 on October 16, 2026, Cronos Group carried a market cap of $1.18B and an enterprise value of $464.0M. The stock trades at a trailing P/E of 16.9x, below the 24.6x median of its US-listed Healthcare peers, but carries a forward P/E of 28.7x compared to the peer median of 17.3x. Its price-to-sales of 6.6x and EV/EBITDA of 51.5x both exceed peer medians of 4.1x and 12.0x, respectively. Over the trailing year, CRON returned 29.4%, outperforming the S&P 500 (SPY) return of 16.8%, though its 5-year return of -41.4% lags the index's 83.0% gain.

Wall Street coverage tracked by Quotelinks includes 4 Strong Buy ratings, 0 Buy ratings, and 1 Hold rating. The mean price target of $2.48 represents a 22.7% discount to the last close of $3.21. For the fiscal year ending December 31, 2026, analysts anticipate an EPS of $0.22 on revenue of $297.9M. For the following fiscal year, 3 analysts project revenue of $399.4M and EPS of $0.25. Cronos Group beat EPS expectations in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Cronos Group Inc. (CRON). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CRON income statement, CRON balance sheet, CRON key metrics, CRON analyst forecast, CRON chart. See the CRON stock overview for the latest quote and news.